tbuckley/cabot-search huggingface dataset:
Editorial
Authors: M Barthet
Journal: Endoscopy (2011)

The French Society of Digestive Endoscopy (SFED) is proud to present here the Abstracts selected for the French Annual meeting of Digestive Diseases (JFHOD). These abstracts will be presented as oral communications and posters. The material consists of all the fields of diagnostic and therapeutic endoscopy, and also includes advanced endoscopy such as therapeutic endoscopic ultrasonography, submucosal dissection or NOTES. A total of more than 600 authors belonging either to National French Society (SNFGE) or to the 1150 members of the SFED have participated in this research effort, leading to the publication of 72 abstracts. Meanwhile, French gastroenterologists, who account for a total number of 3159 practitioners, are participating increasingly in a European endevour to build a participation in research and training for digestive diseases. This was clearly seen in November, France being the forth country for the selected abstracts for UEGW in Barcelona 2010. The SFED is actively working andorganizing the two main Francophone meetings held in France each year, the former being the JFHOD taking place in March in Paris, the latter being Videodigest, held in October. Therefore, French endoscopists are looking forward with a great interest to the next JFHOD which will bring together more than four thousand francophone gastroenterologists.
LHRH
Authors: Joseph A. Smith
Journal: JAMA (1985)

<h3>To the Editor.—</h3> The recent MEDICAL NEWS story<sup>1</sup>on the growing applications for clinical use of luteinizing hormone-releasing hormone (LHRH) provides important updates on the use of this category of drug in the treatment of a number of conditions. With regard to the use of such analogues in the treatment of prostate carcinoma, Ms Ziporyn alluded to recent data<sup>2</sup>that show a rise in serum luteinizing hormone (LH) and testosterone concentrations in patients who have been treated for a mean of 12.7 months with one LHRH analogue (ICI 118630), 250 μg daily. The authors of this article are quoted as stating that LHRH analogues should not be used "as a long-term treatment for carcinoma of the prostate." We have recently reported observations on 98 patients treated for a median of 72 weeks with an LHRH analogue, leuprolide (Lupron), given in 1-mg/day subcutaneous doses.<sup>3</sup>Response rates and duration
Assessment of Environmental Contaminant-Induced Lymphocyte Dysfunction
Authors: Jay B. Silkworth, Leland D. Loose
Journal: Environmental Health Perspectives (1981)

Although it has been established that environmental contaminants can alter immune function, the mechanisms of action have yet to be determined. This paper reviews the effects of hydrocarbon environmental contaminants on lymphocyte function and presents an approach which may serve to delineate the mechanisms of action. The approach is based on the use of the developmental phases of an immune response and assays which can be used for their functional assessment. Possible interactions between environmental contaminants and lymphocyte function and factors which must be considered in the evaluation of immune status are discussed. In addition, a study on the influence of the chronic exposure to two polyhalogenated hydrocarbons, PCB and HCB, on several parameters of lymphocyte function in mice is presented.
Phase II study of dasatinib in patients with advanced non-small cell lung cancer.
Authors: F. M. Johnson, B. N. Bekele, L. Feng, I. I. Wistuba, X. Tang, H. T. Tran, J. J. Erasmus, L. Hwang, N. Takebe, D. J. Stewart
Journal: Journal of Clinical Oncology (2010)

7594 Background: Src-family kinases (SFK) promote cancer progression and are commonly expressed in non-small cell lung cancer (NSCLC). Preclinical data suggest that activation of epidermal growth factor receptor (EGFR) may predict response to SFK inhibition. The clinical effects of SFK inhibition in NSCLC are unknown. Methods: We completed a phase II study of the potent SFK inhibitor dasatinib as first-line therapy for advanced NSCLC. Response was measured by CT scan and metabolic activity by PET scan. Pretreatment tissue was tested for EGFR and K-Ras mutation and for phospho-SFK expression. Results: Thirty four patients with NSCLC were enrolled and treated with an initial dasatinib dose of 100 p.o. BID. An overall disease control rate of 43% was obtained. This included one durable partial response (over 2 years), four with stable disease for over 6 months, and ten additional patients with stable disease. Metabolic (PET) responses were identified in 32%. EGFR and K-Ras mutations and SFK activation in tumor did not predict response. Most patients required dose reduction. Main toxicities included fatigue and dyspnea due to underlying lung disease and pleural effusions. Pleural effusions were expected, and successfully treated with steroids, diuretics, and dose interruptions; baseline effusion predicted development of clinically significant effusion on dasatinib. Conclusions: Dasatinib has moderate clinical activity as a single agent, although lower than generally observed for chemotherapy. Marked activity in one patient and prolonged stable disease in four others indicates a subpopulation of dasatinib-sensitive patients. Supported by the NCI/CTEP, the University of Texas Lung SPORE, and Bristol-Myers Squibb. Author Disclosure Employment or Leadership Position Consultant or Advisory Role Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Bristol-Myers Squibb
Abstract P243: Myocardial Contraction Fraction, Diabetes, and Heart Failure: The Multi-Ethnic Study of Atherosclerosis
Authors: Alain G Bertoni, Elvis A Akwo, David A Bleumke, Joao A Lima, W G Hundley, Haiying Chen, Songtao Liu, Gregory L Burke
Journal: Circulation (2012)

Background: Persons with diabetes mellitus (DM) have altered cardiac structure and function, which increases heart failure (HF) risk. Myocardial contraction fraction (MCF) is an echocardiographic global measure of fractional shortening recently applied to cardiac MRI. We sought to determine if MCF differed by DM status and if MCF predicts HF in the Multi-Ethnic Study of Atherosclerosis, a cohort which enrolled ethnically diverse adults aged 45-84 who were free of clinical CVD. Methods: Analyses included 4991 with MRI data for whom DM status could be ascertained. Left ventricle (LV) volumes and mass (LVM) were calculated by the summation of disks method from cine short axis images. Ejection fraction (EF) is defined as LV stroke volume (SV) / end diastolic luminal volume. MCF is defined as LV SV/ end diastolic myocardial volume. DM was defined as using hypoglycemic drugs or a fasting glucose&gt;125mg/dl. Linear regression was utilized for cross sectional analyses of the association between MCF and DM status, adjusting for age, gender, race/ethnicity, BMI, systolic BP, BP drugs, and smoking. Cox proportional hazards modeling was used to compare MCF, EF and LV mass quartiles as predictors of HF, adjusting for the above variables and DM. Results: At baseline the mean age was 61.5 (SD 10), 52% were female, 39% white, and 61% minorities; 13% had impaired fasting glucose (IFG) and 12% DM. The table indicates LV measurements. After adjustment, DM status remained associated with a lower MCF (IFG -0.02, 95% CI -0.03,-0.01; DM -0.032, 95%CI -0.04, -0.02). There were 96 incident HF events. Compared to the 4 th quartile, the 1 st MCF quartile was associated with HF (adjusted HR 2.2; 95%CI 1.13, 4.43) as was 1 st EF quartile (adjusted HR 2.9; 95%CI 1.6, 5.2) and 4 th quartile LVM (adjusted HR 5.4; 95%CI 2.2, 13.2). Among those with DM, 39% were in the 1 st MCF quartile, compared to 27% in the 1 st EF and 33% in the 4 th LVM quartile. Conclusions: Incident HF is predicted by MCF. MCF may be a more sensitive marker for diabetic cardiomyopathy than EF or LVM. Ventricular Measures by Diabetes Status Glucose Category Parameter Normal 100-125 mg/dl Diabetes p-value MCF 0.66 (0.14) 0.61 (0.14) 0.59 (0.14) &lt;0.001 EF, % 69 (7) 69 (8) 68 (9) 0.11 SV (ml) 87 (20) 86 (19) 86 (19) 0.05 LMV (g) 142 (38) 153 (41) 157 (43) &lt;0.001 Mean (Std Dev)
Sounds in the Attic
Authors: T. P. Duffy
Journal: New England Journal of Medicine (1993)

An 87-year-old woman who had suffered from chronic constipation came to the emergency room and reported having had abdominal pain for two days. It had begun in the lower abdomen while she was straining with a bowel movement. The pain was constant and later covered the entire abdomen. It increased in severity just before she came to the emergency room. She had no vomiting, diarrhea, melena, chills, or fever.The acute onset of constant abdominal pain makes me worry most about a catastrophic cause, such as a ruptured abdominal aneurysm, but there are obviously numerous other possible causes. . . .
AKA
Authors: Zeynep Uzumcu
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Annual Meeting of the American College of Epidemiology
Journal: JNCI Journal of the National Cancer Institute (1982)

Journal Article Annual Meeting of the American College of Epidemiology Get access JNCI: Journal of the National Cancer Institute, Volume 68, Issue 6, June 1982, Page 1043, https://doi.org/10.1093/jnci/68.6.1043-d Published: 01 June 1982
Wacker Revisited
Authors: George N. Braman
Journal: Annals of Internal Medicine (1998)

On Being a Patient1 January 1998Wacker RevisitedGeorge N. Braman, MDGeorge N. Braman, MDBronx, NY 10471.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-128-1-199801010-00012 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail A sharp pain in the back of my neck and left shoulder blade one morning led to a quick trip to the hospital and a ventilation-perfusion scan. The next thing I knew, I was in a hospital bed with a heparin drip.In the next few days, I found myself trying to adjust to the role of hospital patient. I had my Doppler and my venogram. My prothrombin time and partial thromboplastin time were measured regularly. There were the inevitable glitches. The ward nurse, while changing my IV, dropped my Hep-lock on the floor and casually brushed it off. Seeing ... Author, Article, and Disclosure InformationAffiliations: Bronx, NY 10471.Corresponding Author: George N. Braman, MD, 6142 Delafield Avenue, Bronx, NY 10471. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoReframing Gun Violence Frank Davidoff Internists' and Surgeons' Attitudes toward Guns and Firearm Injury Prevention Christine K. Cassel , Elizabeth A. Nelson , Tom W. Smith , C. William Schwab , Barbara Barlow , and Nancy E. Gary Metrics 1 January 1998Volume 128, Issue 1Page: 69KeywordsHeparinNursesPartial thromboplastin timeProthrombin timeSerum glutamic oxaloacetic transaminaseShouldersTachycardiaTechniciansThoraxVentilation perfusion Issue Published: 1 January 1998 Copyright & PermissionsCopyright © 1998 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Mumps in the Workplace
Authors: Karen M. Kaplan
Journal: JAMA (1988)

The first documented mumps outbreak in the workplace took place between August and December of 1987, when 119 cases of mumps occurred among employees at three Chicago futures exchanges and their household contacts. Twenty-one patients developed 23 complications, and nine persons were hospitalized. Total direct and indirect economic costs associated with the outbreak were $120 738; the cost per case was $1473. Only three patients had written documentation of mumps immunization. The outbreak is consistent with the recent changing epidemiology of mumps and the increase in reported cases in the adolescent and young adult populations. Mumps vaccine was licensed in 1967. but its distribution was limited until 1977 when the Immunization Practices Advisory Committee of the US Public Health Service recommended it for universal use. As a result, a cohort of adolescents and young adults underimmunized against mumps and underexposed to disease is now entering the work force. Vaccination of susceptible employees could prevent the substantial health impact of mumps. (<i>JAMA</i>1988;260:1434-1438)
Consensus Statements
Authors: Drummond Rennie
Journal: New England Journal of Medicine (1981)

If you wanted to know whether a new unproved clinical test or operation or a new health program was any good, how would you proceed to find out? The best way would be to set up a controlled clinical trial, comparing the new with the old in everything from morbidity to dollar cost. Such essential trials, however, are always lengthy and very expensive. Each may focus on different aspects of the problem, and although the results of some may be available, others may still be brewing. In the meantime, as a practicing physician you want to advise your patients prudently . . .
Arteriovenous fistula from drug abuse. Implications for hemodialysis
Authors: P. Gabow
Journal: JAMA (1976)

MAJOR surgical complications of intravascular drug abuse, including phlebitis, false aneurysm, and arterial thrombosis, have been reported from this<sup>1</sup>and other institutions.<sup>2,3</sup>Among the major medical problems is an increased incidence of chronic renal disease.<sup>4,5</sup>The unfortunate combination of renal failure and peripheral vascular damage is particularly detrimental to vascular access for longterm hemodialysis. We have seen yet another vascular complication, an arteriovenous fistula of the antecubital fossa that prompted the immediate failure of a Scribner hemodialysis shunt placed in the ipsilateral wrist. <h3>Report of a Case</h3> A 24-year-old man was hospitalized in January 1974, for shortness of breath, fatigue, epistaxis, and syncopal attacks. An episode of hematuria had occurred at the age of 9 years when he was told he had Bright disease. At the age of 17 years, he was rejected for military duty because of proteinuria. He admitted to repeated intravenous use of amphetamines,
BULLET WOUNDS: THEIR INTERPRETATION
Journal: JAMA (1922)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Activation of Proto-Oncogenes in Human and Mouse Lung Tumors
Authors: Steven H. Reynolds, Marshall W. Anderson
Journal: Environmental Health Perspectives (1991)

Lung cancer is a leading cause of cancer-related deaths in several nations. Epidemiological studies have indicated that 85% of all lung cancer deaths and 30% of all cancer deaths in the U.S. are associated with tobacco smoking. Various chemicals in tobacco smoke are thought to react with DNA and to ultimately yield heritable mutations. In an effort to understand the molecular mechanisms involved in lung tumorigenesis, we have analyzed proto-oncogene activation in a series of human lung tumors from smokers and spontaneously occurring and chemically induced lung tumors in mice. Approximately 86% of the human lung tumors and greater than 90% of the mouse lung tumors were found to contain activated oncogenes. ras Oncogenes activated by point mutations were detected in many of the human lung adenocarcinomas and virtually all of the mouse lung adenomas and adenocarcinomas. The mutation profiles of the activated K-ras genes detected in the chemically induced mouse lung tumors suggest that the observed mutations result from genotoxic effects of the chemicals. Comparison of the K-ras mutations observed in the human lung adenocarcinomas with mutation profiles observed in the mouse lung tumors suggest that bulky hydrophobic DNA adducts may be responsible for the majority of the mutations observed in the activated human K-ras genes. Other data indicate that approximately 20% of human lung tumors contain potentially novel transforming genes that may also be targets for mutagens in cigarette smoke.
Plasma Metanephrines in the Diagnosis of Pheochromocytoma
Authors: Jacques W. M. Lenders
Journal: Annals of Internal Medicine (1996)

Letters1 April 1996Plasma Metanephrines in the Diagnosis of PheochromocytomaJacques W. M. Lenders, MD, PhD, Harry R. Keiser, MD, and Graeme Eisenhofer, PhD, PhDJacques W. M. Lenders, MD, PhDSt. Radboud University Hospital; Nijmegen, the NetherlandsNational Institutes of Health; Bethesda, MD 20892Search for more papers by this author, Harry R. Keiser, MDSt. Radboud University Hospital; Nijmegen, the NetherlandsNational Institutes of Health; Bethesda, MD 20892Search for more papers by this author, and Graeme Eisenhofer, PhD, PhDSt. Radboud University Hospital; Nijmegen, the NetherlandsNational Institutes of Health; Bethesda, MD 20892Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-124-7-199604010-00020 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail IN RESPONSE:Dr. Elijovich suggests that the negative predictive value of 100% for plasma free metanephrines used in our study may be misleading because of the low incidence of pheochromocytoma in the general hypertensive population. He further states that the important issue in the diagnosis of pheochromocytoma is how well a test confirms, rather than excludes, the presence of a tumor.As with other biochemical tests, it is neither appropriate nor cost-effective to use plasma metanephrines as a screening test for the hypertensive population at large, and we did not advocate this practice in our report. However, in patients who ...REFERENCE1. Krakoff LR. Searching for pheochromocytoma: a new and better test? [Editorial] Ann Intern Med. 1995; 123:150-1. Google Scholar Author, Article, and Disclosure InformationAffiliations: St. Radboud University Hospital; Nijmegen, the NetherlandsNational Institutes of Health; Bethesda, MD 20892 PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 April 1996Volume 124, Issue 7Page: 695KeywordsBlood plasmaCatecholaminesHealth careMetabolitesNegative predictive valuePheochromocytomaPositive predictive value Issue Published: 1 April 1996 Copyright & PermissionsCopyright © 1996 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Abstract 3557: miR-181a is a key driver of genomic instability and ovarian cancer tumorigenesis through the regulation of RB1
Authors: Matthew Knarr, Lily Kwiatkowski, Anil Nagaraj, Ronny Drapkin, Analisa DiFeo
Journal: Cancer Research (2019)

Abstract Epithelial ovarian cancer (EOC) is one of the deadliest gynecological cancers currently diagnosed in women with approximately 20,000 new cases and 15,000 deaths per year. Ovarian cancer can be stratified into distinct subtypes of which high-grade serous ovarian cancer (HGSOC) comprises 90% of all cases and has the highest mortality rate. Reducing the high mortality rate associated with HGSOC currently has two primary barriers: 1) most HGSOCs are diagnosed at a post-metastatic stage and 2) up to 70% of patients recur within 5 years. Both of these limitations are due to the fact that the drivers of tumor initiation are poorly understood. In order to change the status quo of the last 30 years, a new approach that focuses on understanding the origins of HGSOC is required. Our lab has recently discovered that miR-181a promotes key hallmarks of HGSOC progression in fallopian tube secretory epithelial cells (FTSECs) which are precursor cells of HGSOC. We show that enhanced expression of miR-181a in FTSECs results in increased proliferation, survival, and anchorage independent growth in vitro. Furthermore, FTSECs with miR-181a overexpression are able to form tumors in vivo whereas FTSECs that overexpress a control scramble miRNA cannot. Using cell cycle analysis, dynamic live-cell imaging, and SNP array analysis, we also found that miR-181a overexpression increases aneuploidy and genomic instability in FTSECs. We show that miR-181a promotes defects in nuclear structure, ruptures in the nuclear envelope, as well as mitotic and cytokinetic defects affecting proper chromosome segregation. A combination of global mRNA expression profiling and target prediction software identified the tumor suppressor retinoblastoma (RB1) as a target for miR-181a mediated FTSEC tumorigenesis. Using an RB1 3’UTR luciferase assay, along with stable expression of an shRNA against RB1 in FTSECs, we are able to show that miR-181a directly targets RB1 and that knockdown of RB1 phenocopies miR-181a mediated tumorigenesis. Taken together, our data shed light on a novel mechanism that promotes genomic instability and tumorigenesis in the early phases of HGSOC development. Our results suggest miR-181a as a promising early detection biomarker as well as a prognostic tool to guide patient treatment. Citation Format: Matthew Knarr, Lily Kwiatkowski, Anil Nagaraj, Ronny Drapkin, Analisa DiFeo. miR-181a is a key driver of genomic instability and ovarian cancer tumorigenesis through the regulation of RB1 [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 3557.
Myeloid IRE1a deletion alters hepatic macrophage phenotype and attenuates experimental non-alcoholic steatohepatitis-related hepatocellular carcinoma
Authors: Sanne Van Campenhout, Laurentijn Tilleman, Sander Lefere, Astrid Vandierendonck, Anja Geerts, Xavier Verhelst, Filip Van Nieuwerburgh, Hans Van Vlierberghe, Lindsey Devisscher
Journal: Journal of Hepatology (2020)